You certainly can’t accuse TapImmune’s Glynn Wilson of a lack of confidence. In just five years, the company’s chief executive tells LSIPR in an interview, it will be a billion dollar business. As we note, that’s quite a claim for a company that’s in a highly competitive area, cancer treatment, and is not currently making money.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at email@example.com
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.